» Articles » PMID: 19081646

Trends in Hypercholesterolemia, Treatment and Control Among United States Adults

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2008 Dec 17
PMID 19081646
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Control of hypercholesterolemia is an important clinical and public health objective, yet it is generally poor. The objective of this study was to examine trends in the prevalence of hypercholesterolemia, having a cholesterol check, awareness, treatment, and control among United States adults.

Methods: We examined data for 18053 participants aged > or =20 years of the National Health and Nutrition Examination Surveys from 1999 to 2006.

Results: The unadjusted prevalence of hypercholesterolemia ranged from 53.2% to 56.1% and changed little over the study period. Significant increases were evident in the percentage of United States adults who had their concentration of cholesterol checked (from 68.6% to 74.8%), who reported being told that they had high hypercholesterolemia (from 42.0% to 50.4%), who reported using cholesterol-lowering medications (from 39.1% to 54.4%), and who had their hypercholesterolemia controlled (from 47.0 to 64.3%). Among all participants with hypercholesterolemia control of hypercholesterolemia increased from 7.2% to 17.1%. Disparities related to gender and race or ethnicity existed, notably a lower rate of control among women than men and lower rates of having a cholesterol check and reporting being told about hypercholesterolemia among African Americans and Mexican Americans than whites.

Conclusions: Encouraging increases in awareness, treatment, and control of hypercholesterolemia occurred from 1999 through 2006. Nevertheless, control of hypercholesterolemia remains poor.

Citing Articles

Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis.

Xia Q, Chen Y, Yu Z, Huang Z, Yang Y, Mao A Front Cardiovasc Med. 2023; 10:1186330.

PMID: 37476570 PMC: 10354280. DOI: 10.3389/fcvm.2023.1186330.


Level and trend of total plasma cholesterol in national and subnational of Iran: a systematic review and age-spatio-temporal analysis from 1990 to 2016.

Mehdipour P, Mohammadi E, Sepanlou S, Ahmadvand A, Peykari N, Djalalinia S J Diabetes Metab Disord. 2022; 21(2):1301-1315.

PMID: 35668771 PMC: 9150051. DOI: 10.1007/s40200-022-01052-w.


Health equity in the implementation of genomics and precision medicine: A public health imperative.

Khoury M, Bowen S, Dotson W, Drzymalla E, Green R, Goldstein R Genet Med. 2022; 24(8):1630-1639.

PMID: 35482015 PMC: 9378460. DOI: 10.1016/j.gim.2022.04.009.


Cardiovascular risks before myocardial infarction differences between men and women.

Nystrom A, Stromberg S, Jansson K, Olsen Faresjo A, Faresjo T BMC Cardiovasc Disord. 2022; 22(1):110.

PMID: 35300605 PMC: 8928675. DOI: 10.1186/s12872-022-02555-3.


PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study.

Xu M, Zhu X, Wu J, Zhang Y, Zhao D, Wang X BMC Med. 2022; 20(1):13.

PMID: 35039035 PMC: 8763618. DOI: 10.1186/s12916-021-02208-w.